
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc has demonstrated a robust gross margin of 71.6%, reflecting a significant increase of 980 basis points year-over-year, surpassing market expectations. The company's Light Adjustable Lens (LAL) revenue reached $28.5 million, marking a strong 60% year-over-year growth, while Light Delivery Device (LDD) revenue grew modestly by 7% to $10.7 million. The increasing monthly utilization of LALs per LDD illustrates an upward trend, supporting the potential for sustained double-digit growth driven by an expanding installed base and improved operational metrics.
Bears say
The financial excerpts reflect a concerning trend for RxSight Inc., with LAL utilization growth slowing significantly to +9% year-over-year in the fourth quarter of 2024, down from the previously reported +17%-22% growth range over the prior five quarters. Additionally, US intraocular lens sales appeared flat or declining, potentially due to a weakening cataract surgery market and increased competition, which may have contributed to the overall slowdown in utilization. Lastly, revised earnings per share estimates for 2025 and 2026 indicate a deterioration in financial expectations, alongside highlighted risks such as limited adoption of new technologies, disappointing commercial performance, and potential for dilutive financing rounds, all of which compound the negative outlook.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares